Vaxsafe® MG – Live Mycoplasma Gallisepticum Vaccine

Vaxsafe® MG is a live attenuated Mycoplasma gallisepticum (MG) vaccine derived from the temperature-sensitive ts-11 strain originally developed at the University of Melbourne and manufactured by Bioproperties. Pharmsure acts as the distribution partner for Vaxsafe® MG in selected international markets. The vaccine was developed through chemical mutagenesis and selection for preferential growth at lower temperatures, resulting in a strain that colonises the upper respiratory tract while maintaining a high level of safety in vaccinated birds. Following vaccination, Vaxsafe® MG colonises the mucosal surfaces of the upper respiratory tract and provides continuous antigenic stimulation, supporting protective immunity against virulent field strains of Mycoplasma gallisepticum. Peak immunity is typically achieved within three to four weeks after vaccination.

Extensive laboratory and field studies have demonstrated the strong safety profile of the ts-11 strain. The vaccine is considered virtually non-pathogenic in chickens, is tolerated at a ten-fold overdose, and has shown no evidence of increased pathogenicity following repeated passages in vivo.

Vaccination with Vaxsafe® MG contributes to the reduction of respiratory disease associated with MG infection and can support improved flock productivity. Field studies have reported improvements in egg production, feed conversion, and broiler performance when breeders were vaccinated.

The vaccine is supplied frozen and administered as a single eye-drop dose to chickens, typically between 4 and 14 weeks of age, with one vaccination providing long-lasting protection.

Vaxsafe® MG should be used only in MG-free flocks and in accordance with veterinary guidance and the authorised product instructions.